Language of Resource
Full Text Available
Open Access / OK to Reproduce
BZDs are often a difficult drug class to cease once neuroadaptation has occurred; recommendations usually involve gradual dose reductions of variable rates. A growing body of evidence has suggested that low dose flumazenil, a GABAA receptor antagonist, may be a useful agent to allow for rapid detoxification.
Low dose flumazenil may aid in BZD detoxification in participants taking daily diazepam equivalent at the maximum or above the therapeutic range (≥30 mg) by reducing the need for diazepam.
Randomized double-blind crossover study (n=28)